✦ LIBER ✦

Bevacizumab not cost effective in ovarian cancer

✍ Scribed by Lancsar, Emily; Swait, Joffre

Book ID: 125387053
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2013
Weight: 111 KB
Volume: 685
Category: Article
ISSN: 1173-5503
DOI: 10.1007/s40274-013-0648-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab not cost effective in advanc

Bevacizumab not cost effective in advanced ovarian cancer

✍ Naik, Haladhara; Goswami, Ashok; Kim, Guinyun; Kim, Kwangsoo; Yang, Sung-Chul; S 📂 Article 📅 2014 🏛 Adis International Limited (now part of Wolters Kl ⚖ 199 KB

Bevacizumab + capecitabine not cost effe

Bevacizumab + capecitabine not cost effective in mCRC

✍ Ritter, M.; Mußhoff, O.; Odening, M. 📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl ⚖ 111 KB

Bevacizumab in ovarian cancer

📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 88 KB

Bevacizumab in Ovarian Cancer

✍ Dr Franco Muggia MD 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 120 KB

Pegfilgrastim cost effective in recurren

Pegfilgrastim cost effective in recurrent ovarian cancer

📂 Article 📅 2014 🏛 Adis International Limited (now part of Wolters Kl ⚖ 199 KB

Consolidation paclitaxel is more cost-ef

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced ovarian cancer

✍ J. Lesnock; C. Farris; T. Krivak; K. Smith; M. Markman 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 303 KB